Adverum Biotechnologies (ADVM) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ADVM Stock Alerts $8.93 -0.24 (-2.62%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 2:20 AM | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Rating Reiterated by HC WainwrightMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adverum’s Gene Therapy on Promising Interim Phase 2 Results and Potential Standard of Care Shift in nAMD TreatmentMay 10, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline ProgressMay 10, 2024 | marketbeat.comAdverum Biotechnologies' (ADVM) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Adverum Biotechnologies in a research report on Friday.May 10, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024May 9, 2024 | chron.comAdverum Biotechnologies: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAdverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsMay 9, 2024 | finance.yahoo.comAre Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?May 3, 2024 | globenewswire.comAdverum Biotechnologies to Participate in Upcoming May Investor ConferencesMay 2, 2024 | marketbeat.comHC Wainwright Weighs in on Adverum Biotechnologies, Inc.'s Q1 2024 Earnings (NASDAQ:ADVM)Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Adverum Biotechnologies in a research report issued to clients and investors on Tuesday, April 30th. HC Wainwright analyst M. Caufield antiApril 30, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Rating of "Buy" by AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have been given a consensus rating of "Buy" by the four ratings firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a buy rating. The average 1-year price target among brokeraApril 30, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Research Coverage Started at HC WainwrightHC Wainwright assumed coverage on Adverum Biotechnologies in a report on Tuesday. They set a "buy" rating and a $30.00 target price on the stock.April 29, 2024 | marketbeat.comMizuho Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $22.00Mizuho cut their target price on shares of Adverum Biotechnologies from $40.00 to $22.00 and set a "buy" rating for the company in a research report on Monday.April 25, 2024 | globenewswire.comAdverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingApril 18, 2024 | money.usnews.comAdverum Biotechnologies IncMarch 28, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)March 27, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Decline in Short InterestAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 648,500 shares, a decline of 88.1% from the February 29th total of 5,430,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average daily trading volume, of 231,700 shares, the short-interest ratio is presently 2.8 days.March 22, 2024 | marketbeat.comChardan Capital Comments on Adverum Biotechnologies, Inc.'s FY2024 Earnings (NASDAQ:ADVM)Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities research analysts at Chardan Capital increased their FY2024 EPS estimates for Adverum Biotechnologies in a research report issued on Tuesday, March 19th. Chardan Capital analyst D. Gataulin now expects that the biotechnology comMarch 21, 2024 | markets.businessinsider.comPositive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial PositionMarch 21, 2024 | marketbeat.comTrading was temporarily halted for "ADVM" at 07:03 PM with a stated reason of "News pending."March 20, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial AdjustmentsMarch 19, 2024 | finance.yahoo.comIs Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?March 19, 2024 | marketbeat.comChardan Capital Reiterates Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM)Chardan Capital reaffirmed a "buy" rating and set a $4.00 price objective on shares of Adverum Biotechnologies in a report on Tuesday.March 19, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $2.00 at Royal Bank of CanadaRoyal Bank of Canada decreased their target price on shares of Adverum Biotechnologies from $3.00 to $2.00 and set a "sector perform" rating on the stock in a research note on Tuesday.March 19, 2024 | markets.businessinsider.comAdverum Biotechnologies (ADVM) Receives a Buy from TD CowenMarch 18, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023March 18, 2024 | globenewswire.comAdverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesMarch 17, 2024 | seekingalpha.comADVM Adverum Biotechnologies, Inc.March 8, 2024 | marketbeat.comFmr LLC Sells 1,069,367 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Fmr LLC lowered its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 13.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,691,925 shares of the biotechnology company's stock after selling 1,069,36March 6, 2024 | finance.yahoo.comADVM Apr 2024 5.000 callMarch 6, 2024 | investorplace.comTurn Pocket Change into Profit: 3 Penny Stocks Ready to PopFebruary 28, 2024 | globenewswire.comAdverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsFebruary 25, 2024 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 10.53% to 4.28February 22, 2024 | benzinga.comAdverum Biotechnologies Stock (NASDAQ:ADVM), Short Interest ReportFebruary 22, 2024 | investorplace.comUnleash Massive Returns With These 3 Top Penny StocksFebruary 15, 2024 | finance.yahoo.comADVM Feb 2024 4.000 callFebruary 13, 2024 | finance.yahoo.comADVM Sep 2024 2.500 putFebruary 13, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Decrease in Short InterestAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,220,000 shares, a drop of 26.1% from the January 15th total of 1,650,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.4% of the shares of the company are sold short.February 12, 2024 | finance.yahoo.comAdverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 9, 2024 | uk.investing.comAdverum Biotechnologies Inc (ADVM)February 9, 2024 | marketbeat.comJames Paul Scopa Buys 100,000 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) Director James Paul Scopa bought 100,000 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average cost of $1.35 per share, with a total value of $135,000.00. Following the acquisition, the director now directly owns 100,000 shares of the company's stock, valued at $135,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.February 8, 2024 | msn.comWhy Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?February 8, 2024 | finance.yahoo.comAdverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDFebruary 8, 2024 | marketbeat.comTrading was temporarily halted for "ADVM" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | msn.comAdverum Biotechnologies Awaits Court Decision on SettlementFebruary 6, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Given New $4.00 Price Target at MizuhoMizuho raised their price objective on Adverum Biotechnologies from $2.00 to $4.00 and gave the company a "buy" rating in a research note on Tuesday.February 6, 2024 | msn.comAdverum Biotechnologies Secures $127.8M in Private PlacementFebruary 6, 2024 | msn.comAdverum Biotechnologies Executes Private Equity PlacementFebruary 5, 2024 | msn.comAdverum Biotechnologies, Cano Health among healthcare movers Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address My system predicted the BA collapse – now it’s issuing an AI warning (Ad)Even after several plane crashes and equipment malfunctions... a congressional hearing... and the worst PR firestorm in recent memory... The FTC's commission chair Lina Khan still deems Boeing (BA), "too big to fail" Click to see why a similar situation is currently brewing in the AI market... ADVM Media Mentions By Week ADVM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼0.130.57▲Average Medical News Sentiment ADVM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼131▲ADVM Articles Average Week Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IPHA News IPSC News KOD News INMB News ABOS News ZURA News CMPX News OPT News CGEN News ELEV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADVM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
